Screening of Ototoxicity and Otoprotective Drugs

Screening of Ototoxicity and Otoprotective Drugs

1. Definition, scope & rationale of ototoxicity screening

• Ototoxicity = permanent or transient impairment of cochlear (hearing) and/or vestibular (balance) function caused by therapeutic drugs or other exogenous insults; hearing can be permanently impaired by therapeutic drugs, most notably the aminoglycoside class of antibiotics and the platinum-based chemotherapeutic drugs (Vogel 4e — Inner-Ear Damage Assays, p.3791).
• The high prevalence of drug-induced hearing loss in patients has driven interest in two goals that ototoxicity assays are built to serve: understanding the mechanism of injury and preventing it (screening candidate protectants) (Vogel 4e — Inner-Ear Damage Assays, p.3791).
• Screening ototoxicity and screening otoprotection are the two mirror-image experimental questions: an assay that reliably induces a graded, reproducible hair-cell lesion can be used both to rank the toxicity of new drug candidates and to test the efficacy of putative protective agents co-administered against a standard ototoxic insult (Vogel 4e — Inner-Ear Damage Assays, pp.3792–3796).
• Characteristic clinical signature the models aim to reproduce: aminoglycoside ototoxicity usually affects hearing in the high-frequency range first, progressing to lower frequencies — a base-to-apex cochlear gradient that the validated models deliberately mirror (Vogel 4e — Inner-Ear Damage Assays, p.3791).
• Two-tier screening logic (in-vitro → in-vivo): the organotypic organ of Corti explant provides a rapid, sensitive in-vitro first pass; promising protectants are then confirmed in an intact-organism in-vivo model (guinea pig for aminoglycosides). The in-vitro assay's efficiency "allows relatively rapid evaluation prior to investing the time and expense of in-vivo studies" (Vogel 4e — Inner-Ear Damage Assays, pp.3792, 3799).
• Validity heuristic used throughout the field: a protective effect is considered compelling when protection observed in one in-vitro/animal study reproduces in a different in-vivo species — cross-model, cross-species concordance is the standard of evidence (Vogel 4e — Inner-Ear Damage Assays, p.3799).
• Acquired hearing loss covered by these assay families: (i) drug-induced (aminoglycoside, cisplatin) inner-ear damage; (ii) noise-induced hearing loss (NIHL); (iii) age-related hearing loss (ARHL / presbycusis) — noise and aging contributions are "distinct, yet interrelated" and share an oxidative-stress mechanism, so their models overlap heavily in endpoints (Vogel 4e — NIHL/ARHL Models, p.3829).
• Unifying mechanistic theme across insults: a significant body of evidence attributes cochlear damage (aminoglycoside, noise, aging) to reactive oxygen species / free-radical production and oxidative-metabolic stress in hair cells — which is why the reference protectant class in every model is antioxidants (Vogel 4e — NIHL/ARHL Models, pp.3831, 3833; Inner-Ear Damage Assays, p.3799).